Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

Osimertinib is designed to target the secondary resistant EGFR T790M mutant and has shown outstanding clinical efficacy. However, the prognostic prediction of osimertinib patients is a big problem in clinical practice. The resistance mechanism of osimertinib is also not fully understood. NGS and a 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Xing, Puyuan, Han, Xiaohong, Wang, Sha, Liu, Yutao, Yang, Sheng, Hao, Xuezhi, Wang, Yan, Liu, Peng, Li, Junling, Wang, Lin, Chang, Lianpeng, Guan, Yanfang, Zhang, Zhishang, Wu, Di, Yao, Jiarui, Yi, Xin, Shi, Yuankai
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6787503/
https://ncbi.nlm.nih.gov/pubmed/31393074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14565
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados